BioMarin Pharmaceutical (BMRN) was slipping past 8% after saying the US Food and Drug Administration has placed its phase 1/2 trial of BMN 307 gene therapy in adults with phenylketonuria, a type of genetic disorder, on clinical hold following interim safety data from a pre-clinical study in mice.
Adaptimmune Therapeutics (ADAP) was rallying past 24% after saying it entered into a strategic collaboration and license agreement with Genentech to develop and commercialize allogeneic cell therapies for the treatment of multiple oncology indications.
TransMedics Group (TMDX) was gaining nearly 4% after saying the US Food and Drug Administration has granted premarket approval of its OCS Heart System for use with organs from donors after brain death.
|--BofA Securities Raises Square's Price Target to $2...|
|BofA Securities Downgrades PTC Therapeutics to Under...|
|DA Davidson Adjusts PNC Financial Services Group PT ...|
|Digital Ally Receives Orders For Body-Worn Camera, D...|
|Loop Capital Upgrades FMC to Buy from Hold, Keeps $1...|